Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma

被引:6
作者
Kong, Hui [1 ]
Zhu, Haojie [1 ]
Zheng, Xiaoyun [1 ]
Jiang, Meichen [2 ]
Chen, Lushan [2 ]
Lan, Lingqiong [3 ]
Ren, Jinhua [1 ]
Luo, Xiaofeng [1 ]
Zheng, Jing [1 ]
Zheng, Zhihong [1 ]
Chen, Zhizhe [1 ]
Hu, Jianda [1 ]
Yang, Ting [1 ]
机构
[1] Fujian Med Univ Union Hosp, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China
[2] Fujian Med Univ Union Hosp, Dept Pathol, Fuzhou, Peoples R China
[3] Second Hosp Longyan, Dept Hematol, Longyan, Peoples R China
基金
中国国家自然科学基金;
关键词
high-grade B-cell lymphoma; clinical characteristics; diagnostic predictor; machine learning; classification models; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; DOUBLE-HIT LYMPHOMA; PROTEIN EXPRESSION; HODGKINS-DISEASE; BURKITT-LYMPHOMA; MYC; BCL2; SURVIVAL; OUTCOMES; IMPACT;
D O I
10.3389/fimmu.2022.919012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
High-grade B-cell lymphoma (HGBL) is a newly introduced category of rare and heterogeneous invasive B-cell lymphoma (BCL), which is diagnosed depending on fluorescence in situ hybridization (FISH), an expensive and laborious analysis. In order to identify HGBL with minimal workup and costs, a total of 187 newly diagnosed BCL patients were enrolled in a cohort study. As a result, the overall survival (OS) and progression-free survival (PFS) of the HGBL group were inferior to those of the non-HGBL group. HGBL (n = 35) was more likely to have a high-grade histomorphology appearance, extranodal involvement, bone marrow involvement, and whole-body maximum standardized uptake (SUVmax). The machine learning classification models indicated that histomorphology appearance, Ann Arbor stage, lactate dehydrogenase (LDH), and International Prognostic Index (IPI) risk group were independent risk factors for diagnosing HGBL. Patients in the high IPI risk group, who are CD10 positive, and who have extranodal involvement, high LDH, high white blood cell (WBC), bone marrow involvement, old age, advanced Ann Arbor stage, and high SUVmax had a higher risk of death within 1 year. In addition, these models prompt the clinical features with which the patients should be recommended to undergo a FISH test. Furthermore, this study supports that first-line treatment with R-CHOP has dismal efficacy in HGBL. A novel induction therapeutic regimen is still urgently needed to ameliorate the poor outcome of HGBL patients.
引用
收藏
页数:11
相关论文
共 36 条
[1]   Double-hit B-cell lymphomas [J].
Aukema, Sietse M. ;
Siebert, Reiner ;
Schuuring, Ed ;
van Imhoff, Gustaaf W. ;
Kluin-Nelemans, Hanneke C. ;
Boerma, Evert-Jan ;
Kluin, Philip M. .
BLOOD, 2011, 117 (08) :2319-2331
[2]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[3]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[4]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[5]   Double-hit lymphomas: current paradigms and novel treatment approaches [J].
Dunleavy, Kieron .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, :107-112
[6]   Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience [J].
Foot, Nicola J. ;
Dunn, Robert G. ;
Geoghegan, Helen ;
Wilkins, Bridget S. ;
Neat, Michael J. .
JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (09) :802-808
[7]   Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [J].
Green, Tina Marie ;
Young, Ken H. ;
Visco, Carlo ;
Xu-Monette, Zijun Y. ;
Orazi, Attilio ;
Go, Ronald S. ;
Nielsen, Ole ;
Gadeberg, Ole V. ;
Mourits-Andersen, Torben ;
Frederiksen, Mikael ;
Pedersen, Lars Moller ;
Moller, Michael Boe .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3460-3467
[8]   Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Delabie, J ;
Ott, G ;
Müller-Hermelink, HK ;
Campo, E ;
Braziel, RM ;
Jaffe, ES ;
Pan, ZG ;
Farinha, P ;
Smith, LM ;
Falini, B ;
Banham, AH ;
Rosenwald, A ;
Staudt, LM ;
Connors, JM ;
Armitage, JO ;
Chan, WC .
BLOOD, 2004, 103 (01) :275-282
[9]   The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH [J].
Hilton, Laura K. ;
Tang, Jeffrey ;
Ben-Neriah, Susana ;
Alcaide, Miguel ;
Jiang, Aixiang ;
Grande, Bruno M. ;
Rushton, Christopher K. ;
Boyle, Merrill ;
Meissner, Barbara ;
Scott, David W. ;
Morin, Ryan D. .
BLOOD, 2019, 134 (18) :1528-1532
[10]   MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma [J].
Horn, Heike ;
Ziepert, Marita ;
Becher, Claudia ;
Barth, Thomas F. E. ;
Bernd, Heinz-Wolfram ;
Feller, Alfred C. ;
Klapper, Wolfram ;
Hummel, Michael ;
Stein, Harald ;
Hansmann, Martin-Leo ;
Schmelter, Christopher ;
Moeller, Peter ;
Cogliatti, Sergio ;
Pfreundschuh, Michael ;
Schmitz, Norbert ;
Truemper, Lorenz ;
Siebert, Reiner ;
Loeffler, Markus ;
Rosenwald, Andreas ;
Ott, German .
BLOOD, 2013, 121 (12) :2253-2263